Literature DB >> 26634651

APOL1 Genotype, Kidney and Cardiovascular Disease, and Death in Older Adults.

Kenneth J Mukamal1, Joseph Tremaglio2, David J Friedman2, Joachim H Ix2, Lewis H Kuller2, Russell P Tracy2, Martin R Pollak2.   

Abstract

OBJECTIVE: We sought to evaluate the cardiovascular impact of coding variants in the apolipoprotein L1 gene APOL1 that protect against trypanosome infection but have been associated with kidney disease among African Americans. APPROACH AND
RESULTS: As part of the Cardiovascular Health Study, a population-based cohort of Americans aged ≥65 years, we genotyped APOL1 polymorphisms rs73885319 and rs71785153 and examined kidney function, subclinical atherosclerosis, and incident cardiovascular disease and death over 13 years of follow-up among 91 African Americans with 2 risk alleles, 707 other African Americans, and 4964 white participants. The high-risk genotype with 2 risk alleles was associated with 2-fold higher levels of albuminuria and lower ankle-brachial indices but similar carotid intima-media thickness among African Americans. Median survival among high-risk African Americans was 9.9 years (95% confidence interval [CI], 8.7-11.9), compared with 13.6 years (95% CI, 12.5-14.3) among other African Americans and 13.3 years (95% CI, 13.0-13.6) among whites (P=0.03). The high-risk genotype was also associated with increased risk for incident myocardial infarction (adjusted hazard ratio 1.8; 95% CI, 1.1-3.0) and mortality (adjusted hazard ratio 1.3; 95% CI 1.0-1.7). Albuminuria and risk for myocardial infarction and mortality were nearly identical between African Americans with 0 to 1 risk alleles and whites.
CONCLUSIONS: APOL1 genotype is associated with albuminuria, subclinical atherosclerosis, incident myocardial infarction, and mortality in older African Americans. African Americans without 2 risk alleles do not differ significantly in risk of myocardial infarction or mortality from whites. APOL1 trypanolytic variants may account for a substantial proportion of the excess risk of chronic disease in African Americans.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  albuminuria; apolipoproteins; epidemiology; genetics; kidney; myocardial infarction

Mesh:

Substances:

Year:  2015        PMID: 26634651      PMCID: PMC4732891          DOI: 10.1161/ATVBAHA.115.305970

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  32 in total

1.  Population-based risk assessment of APOL1 on renal disease.

Authors:  David J Friedman; Julia Kozlitina; Giulio Genovese; Prachi Jog; Martin R Pollak
Journal:  J Am Soc Nephrol       Date:  2011-10-13       Impact factor: 10.121

2.  Mortality from homicide among young Black men: a new American tragedy.

Authors:  Charles H Hennekens; Joanna Drowos; Robert S Levine
Journal:  Am J Med       Date:  2013-01-16       Impact factor: 4.965

3.  APOL1 variants and kidney disease in people of recent African ancestry.

Authors:  Giulio Genovese; David J Friedman; Martin R Pollak
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

4.  The association of microalbuminuria with clinical cardiovascular disease and subclinical atherosclerosis in the elderly: the Cardiovascular Health Study.

Authors:  Jie J Cao; Joshua I Barzilay; Do Peterson; Teri A Manolio; Bruce M Psaty; Lewis Kuller; Jason Wexler; Anthony J Bleyer; Mary Cushman
Journal:  Atherosclerosis       Date:  2005-10-20       Impact factor: 5.162

Review 5.  The trypanolytic factor of human serum.

Authors:  Etienne Pays; Benoit Vanhollebeke; Luc Vanhamme; Françoise Paturiaux-Hanocq; Derek P Nolan; David Pérez-Morga
Journal:  Nat Rev Microbiol       Date:  2006-06       Impact factor: 60.633

6.  APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy.

Authors:  Jeffrey B Kopp; George W Nelson; Karmini Sampath; Randall C Johnson; Giulio Genovese; Ping An; David Friedman; William Briggs; Richard Dart; Stephen Korbet; Michele H Mokrzycki; Paul L Kimmel; Sophie Limou; Tejinder S Ahuja; Jeffrey S Berns; Justyna Fryc; Eric E Simon; Michael C Smith; Howard Trachtman; Donna M Michel; Jeffrey R Schelling; David Vlahov; Martin Pollak; Cheryl A Winkler
Journal:  J Am Soc Nephrol       Date:  2011-10-13       Impact factor: 10.121

7.  African ancestry, socioeconomic status, and kidney function in elderly African Americans: a genetic admixture analysis.

Authors:  Carmen A Peralta; Elad Ziv; Ronit Katz; Alex Reiner; Esteban González Burchard; Linda Fried; Pui-Yan Kwok; Bruce Psaty; Michael Shlipak
Journal:  J Am Soc Nephrol       Date:  2006-11-02       Impact factor: 10.121

8.  Quantifying the burden of rhodesiense sleeping sickness in Urambo District, Tanzania.

Authors:  Lucas E Matemba; Eric M Fèvre; Stafford N Kibona; Kim Picozzi; Sarah Cleaveland; Alexandra P Shaw; Susan C Welburn
Journal:  PLoS Negl Trop Dis       Date:  2010-11-02

9.  Black-white differences in subclinical cardiovascular disease among older adults: the Cardiovascular Health Study. CHS Collaborative Research Group.

Authors:  T A Manolio; G L Burke; B M Psaty; A B Newman; M Haan; N Powe; R P Tracy; D H O'Leary
Journal:  J Clin Epidemiol       Date:  1995-09       Impact factor: 6.437

10.  Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene.

Authors:  Shay Tzur; Saharon Rosset; Revital Shemer; Guennady Yudkovsky; Sara Selig; Ayele Tarekegn; Endashaw Bekele; Neil Bradman; Walter G Wasser; Doron M Behar; Karl Skorecki
Journal:  Hum Genet       Date:  2010-07-16       Impact factor: 4.132

View more
  46 in total

Review 1.  ApoL1 and the Immune Response of Patients with Systemic Lupus Erythematosus.

Authors:  Ashira D Blazer; Robert M Clancy
Journal:  Curr Rheumatol Rep       Date:  2017-03       Impact factor: 4.592

Review 2.  Hypertension in African Americans.

Authors:  Nomsa Musemwa; Crystal A Gadegbeku
Journal:  Curr Cardiol Rep       Date:  2017-10-28       Impact factor: 2.931

Review 3.  The Impact of APOL1 on Chronic Kidney Disease and Hypertension.

Authors:  Todd W Robinson; Barry I Freedman
Journal:  Adv Chronic Kidney Dis       Date:  2019-03       Impact factor: 3.620

4.  Strict blood pressure control associates with decreased mortality risk by APOL1 genotype.

Authors:  Elaine Ku; Michael S Lipkowitz; Lawrence J Appel; Afshin Parsa; Jennifer Gassman; David V Glidden; Miroslaw Smogorzewski; Chi-Yuan Hsu
Journal:  Kidney Int       Date:  2016-12-04       Impact factor: 10.612

5.  APOL1 renal-risk genotypes associate with longer hemodialysis survival in prevalent nondiabetic African American patients with end-stage renal disease.

Authors:  Lijun Ma; Carl D Langefeld; Mary E Comeau; Jason A Bonomo; Michael V Rocco; John M Burkart; Jasmin Divers; Nicholette D Palmer; Pamela J Hicks; Donald W Bowden; Janice P Lea; Jenna O Krisher; Margo J Clay; Barry I Freedman
Journal:  Kidney Int       Date:  2016-05-06       Impact factor: 10.612

Review 6.  The African diaspora: history, adaptation and health.

Authors:  Charles N Rotimi; Fasil Tekola-Ayele; Jennifer L Baker; Daniel Shriner
Journal:  Curr Opin Genet Dev       Date:  2016-09-16       Impact factor: 5.578

7.  Apolipoprotein L1 Testing in African Americans: Involving the Community in Policy Discussions.

Authors:  Bessie A Young; Erika Blacksher; Kerri L Cavanaugh; Barry I Freedman; Stephanie M Fullerton; Jeffrey B Kopp; Ebele M Umeukeje; Kathleen M West; James G Wilson; Wylie Burke
Journal:  Am J Nephrol       Date:  2019-09-03       Impact factor: 3.754

Review 8.  The genomic landscape of African populations in health and disease.

Authors:  Charles N Rotimi; Amy R Bentley; Ayo P Doumatey; Guanjie Chen; Daniel Shriner; Adebowale Adeyemo
Journal:  Hum Mol Genet       Date:  2017-10-01       Impact factor: 6.150

Review 9.  HDL in CKD-The Devil Is in the Detail.

Authors:  Florian Kronenberg
Journal:  J Am Soc Nephrol       Date:  2018-02-22       Impact factor: 10.121

10.  APOL1 and Cardiovascular Disease: A Story in Evolution.

Authors:  Archna Bajaj; Katalin Susztak; Scott M Damrauer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-09       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.